Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 8Lymphoma 7Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Recurrence 3Neoplasms 2Leukemia, B-Cell 2Burkitt Lymphoma 2Neoplasm, Residual 1Mature B-Cell Malignancies 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Heart Failure 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1

Interventions

obinutuzumab 1glofitamab 1fludarabine phosphate 1Whole-Body Irradiation 1Tacrolimus 1Sirolimus 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1Methotrexate 1Melphalan 1Etoposide 1Cyclosporine 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × obinutuzumab × 30 days × Clear all
NCT04889716 2026-05-26

CAR-T Followed by Bispecific Antibodies

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
23 enrolled
Sarcoma

Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡